ArticleCancer discovery2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 95 citations in OpenAlex.
- Article
- Histone Variant H2A.Z2 Hyper-Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK-STAT Signaling Pathway.Thoracic cancer · 2026Article
- Metabolic permissiveness: how tissue context shapes cancer.Genes & development · 2026Review
- Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy.Current oncology reports · 2026Review
- Induction of cellular senescence by androgen receptor agonist or antagonist is mediated via two novel common DYRK1A-DREAM and cyclin G2 signaling pathways in castration-resistant prostate cancer.Journal of advanced research · 2026Article
- SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration.Molecular & cellular oncology · 2026Article
- USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression.Cell communication and signaling : CCS · 2025Article
- Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes.Cell death and differentiation · 2025Article
- The dual guardians of cellular stability: exploring nesprin and lamin in senescence.Cell death & disease · 2025Review
- New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.EMBO molecular medicine · 2025Review
- Regulation of ferroptosis by transcription factor E2F1.Biochimie · 2025Article
- Clonorchis sinensis-driven hepatocarcinogenesis via E2F1-CD24 transcriptional axis: mechanistic and therapeutic implications.Parasites & vectors · 2025Article
- Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing.Scientific reports · 2025Article
- Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment.World journal of gastroenterology · 2025Article
- CDK-4 regulates nucleolar size and metabolism at the cost of late-life fitness in C. elegans.Heredity · 2025Article
- The interplay between angiogenesis-associated genes and molecular, clinical, and immune features in bladder cancer.Discover oncology · 2025Article
- KRASCell reports. Medicine · 2025Article
- New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.Research (Washington, D.C.) · 2025Review
- NAT10-mediated N4-acetylcytosine modification promotes the progression of retinoblastoma by improving the HK1 mRNA stability to enhance glycolysis.Clinics (Sao Paulo, Brazil) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 3 countries.
Amy C MandigoDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-4683-5268
Wei YuanThe Institute of Cancer Research, London, United Kingdom.
Kexin XuThe University of Texas Health Science Center at San Antonio, San Antonio, Texas.ORCID 0000-0002-2850-2083
Peter GallagherDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Angel PangSchool of Medical Sciences and Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Yi Fang GuanSchool of Medical Sciences and Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Ayesha A ShafiDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-0335-638X
Chellappagounder ThangavelDepartments of Urology, Medical Oncology and Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-5179-9364
Beshara SheehanThe Institute of Cancer Research, London, United Kingdom.
Denisa BogdanThe Institute of Cancer Research, London, United Kingdom.
Alec PaschalisThe Institute of Cancer Research, London, United Kingdom.
Jennifer J McCannDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Talya S LauferDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Nicolas GordonDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Irina A VasilevskayaDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-7550-5001
Emanuela DylgjeriDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Saswati N ChandDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-5625-0517
Matthew J SchiewerDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Josep Domingo-DomenechDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Robert B DenDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Jeff HolstDepartment of Dermatology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-0377-9318
Peter A McCueDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Johann S de BonoThe Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-2034-595X
Christopher McNairDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0003-3204-8482
Karen E KnudsenDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania. karen.knudsen@jefferson.edu.
Thomas Jefferson University · USRoyal Marsden NHS Foundation Trust · GBUNSW Sydney · AUThe University of Texas Health Science Center at San Antonio · US
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8MUSP22 Function in Advanced Prostate CancerR01CA182569 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E, MCMAHON, STEVEN B. · 2015 to 2019
$2.4MDetermine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancerR01CA261925 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Josep Maria Domingo-Domenech · 2021 to 2026
$2.2MRole of GATA2 signaling network in Lethal Prostate CancerR01CA207311 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DOMINGO-DOMENECH, JOSEP MARIA · 2016 to 2020
$2.2MRB Function in Prostate Cancer ProgressionR01CA176401 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E · 2014 to 2018
$2.2MTargeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate CancerR01CA217329 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KELLY, WILLIAM K., MCNAIR, CHRISTOPHER MICHAEL · 2017 to 2021
$1.8MTraining Program in Cellular, Biochemical, and Molecular SciencesT32GM100836 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI BENOVIC, JEFFREY L · 2012 to 2016
$809kThe Role of USP22 in Prostate Cancer Development and ProgressionF99CA212225 · NCI · THOMAS JEFFERSON UNIVERSITY · PI MCCANN, JENNIFER JONES · 2016 to 2017
$89kNCI NIH HHS F99 CA212225NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA176401NCI NIH HHS R01 CA182569NCI NIH HHS R01 CA207311NCI NIH HHS R01 CA217329NCI NIH HHS R01 CA261925NIGMS NIH HHS T32 GM100836
Abstract
Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss on cell-cycle regulation. Here, isogenic modeling of RB loss identified disease stage-specific rewiring of E2F1 function, providing the first-in-field mapping of the E2F1 cistrome and transcriptome after RB loss across disease progression. Biochemical and functional assessment using both
Indexed as
AnimalsCell Line, TumorE2F1 Transcription FactorHumansMiceNeoplasm MetastasisRetinal NeoplasmsRetinoblastomaRetinoblastoma ProteinSignal TransductionXenograft Model Antitumor AssaysE2F1 protein, humanE2F1 Transcription FactorRetinoblastoma Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.